LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

67.83 -1.18

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.7

Max

69.27

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.5M -190M
Verkoop	33M 154M
Winstmarge	-123.403
Werknemers	834
EBITDA	-6.9M -180M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+52.2% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	361M 13B
Vorige openingsprijs	69.01
Vorige sluitingsprijs	67.83

Nieuwssentiment

By Acuity

25%

75%

50 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.71 / 36.9 Steun & Weerstand

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mei 2026, 23:41 UTC

Winsten

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mei 2026, 21:40 UTC

Winsten

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mei 2026, 23:34 UTC

Marktinformatie

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mei 2026, 23:13 UTC

Winsten

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mei 2026, 23:12 UTC

Winsten

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mei 2026, 23:11 UTC

Winsten

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mei 2026, 23:11 UTC

Winsten

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mei 2026, 23:07 UTC

Winsten

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mei 2026, 23:06 UTC

Winsten

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mei 2026, 23:05 UTC

Winsten

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mei 2026, 23:04 UTC

Winsten

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mei 2026, 22:50 UTC

Winsten

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mei 2026, 22:25 UTC

Marktinformatie

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mei 2026, 22:11 UTC

Winsten

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mei 2026, 22:05 UTC

Marktinformatie

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mei 2026, 21:58 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:47 UTC

Marktinformatie

Winsten

Costco Posts 13% Sales Growth in April -- Market Talk

6 mei 2026, 21:46 UTC

Winsten

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mei 2026, 21:40 UTC

Winsten

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mei 2026, 21:35 UTC

Marktinformatie

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mei 2026, 21:32 UTC

Populaire aandelen

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mei 2026, 21:29 UTC

Winsten

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

52.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 105 USD 52.2%

Hoogste 157 USD

Laagste 81 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

50 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.